肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
5期
339-341
,共3页
食管肿瘤%放射疗法%药物疗法%预后
食管腫瘤%放射療法%藥物療法%預後
식관종류%방사요법%약물요법%예후
Esophageal neoplasms%Radiotherapy%Drug therapy%Prognosis
目的 探讨铂类单药化疗联合同期放疗治疗非手术食管癌的远期疗效.方法 2008年4月至2010年2月首诊的无远处转移食管癌患者47例,化疗采用奈达铂或顺铂20 mg/m2,每周1次.同期放疗采用常规分割,200 cGy/次,1次/d,5d/周,放疗总量60 ～ 70 Gy.结果 47例患者的1、2、3、4年生存率分别为63.83％(30/47)、40.43 ％(19/47)、38.30％(18/47)、30.77 ％(4/13).13例有淋巴结转移患者的4年生存率为0,与无淋巴结转移者的40％(4/10)相比,差异有统计学意义(x 2=6.295,P=0.012).顺铂联合同期放疗组3年生存率为31.25％(5/16),与奈达铂联合同期放疗组的41.94％(13/31)比较,差异无统计学意义(x 2=0.510,P=0.475).结论 铂类单药化疗联合同期放疗治疗非手术食管癌是安全的,远期疗效有待大规模临床试验证实.
目的 探討鉑類單藥化療聯閤同期放療治療非手術食管癌的遠期療效.方法 2008年4月至2010年2月首診的無遠處轉移食管癌患者47例,化療採用奈達鉑或順鉑20 mg/m2,每週1次.同期放療採用常規分割,200 cGy/次,1次/d,5d/週,放療總量60 ～ 70 Gy.結果 47例患者的1、2、3、4年生存率分彆為63.83％(30/47)、40.43 ％(19/47)、38.30％(18/47)、30.77 ％(4/13).13例有淋巴結轉移患者的4年生存率為0,與無淋巴結轉移者的40％(4/10)相比,差異有統計學意義(x 2=6.295,P=0.012).順鉑聯閤同期放療組3年生存率為31.25％(5/16),與奈達鉑聯閤同期放療組的41.94％(13/31)比較,差異無統計學意義(x 2=0.510,P=0.475).結論 鉑類單藥化療聯閤同期放療治療非手術食管癌是安全的,遠期療效有待大規模臨床試驗證實.
목적 탐토박류단약화료연합동기방료치료비수술식관암적원기료효.방법 2008년4월지2010년2월수진적무원처전이식관암환자47례,화료채용내체박혹순박20 mg/m2,매주1차.동기방료채용상규분할,200 cGy/차,1차/d,5d/주,방료총량60 ～ 70 Gy.결과 47례환자적1、2、3、4년생존솔분별위63.83％(30/47)、40.43 ％(19/47)、38.30％(18/47)、30.77 ％(4/13).13례유림파결전이환자적4년생존솔위0,여무림파결전이자적40％(4/10)상비,차이유통계학의의(x 2=6.295,P=0.012).순박연합동기방료조3년생존솔위31.25％(5/16),여내체박연합동기방료조적41.94％(13/31)비교,차이무통계학의의(x 2=0.510,P=0.475).결론 박류단약화료연합동기방료치료비수술식관암시안전적,원기료효유대대규모림상시험증실.
Objective To evaluate the therapeutic effects of platinum alone chemotherapy combined with radiotherapy for esophageal carcinoma without operation.Methods Form April 2008 to February 2010,47 initial treatment patients with esophageal carcinoma were treated by platinum alone chemotherapy (cisplatin or nedaplatin 20 mg/m2,one times per weeks) and conventional fractionated radiation therapy (200 cGy per fraction,2 times per day,5 days per week,to a total dose of 6 000-7 000 cGy).Results 1-,2-,3-,4-year overall survival rates were 63.83 ％ (30/47),40.43 ％ (19/47),38.30 ％ (18/47),30.77 ％ (4/13).4-year survival rate of 13 cases with lymph node metastasis was 0,it was lower than that of cases without lymph node metastasis (40 ％,4/10),the difference was statistically significant (x2 =6.295,P =0.012).The 3-year survival rates in cisplatin or nedaplatin combined with radiotherapy group were 31.25 ％ (5/16) and 41.94 ％ (13/31),the difference was not statistically significant (x2 =0.510,P =0.475).Conclusion Low doses of platinum alone chemotherapy combined with radiotherapy for the treatment of esophageal cancer are safe,but long-term efficacy needs to be confirmed in larger clinical trials.
